2019
DOI: 10.1007/s00120-019-0953-y
|View full text |Cite
|
Sign up to set email alerts
|

Einsatz von Docetaxel oder Abirateron in Kombination mit einer Androgendeprivationstherapie beim metastasierten hormonnaiven Prostatakarzinom

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
4
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(4 citation statements)
references
References 37 publications
0
4
0
Order By: Relevance
“…However, once castration resistance is acquired, it will not respond to ADT, and recurrence and metastasis will occur as castration‐resistant prostate cancer (CRPC). Recently, various novel hormone treatment drugs and their combinations have appeared, 2–5 but docetaxel (DTX) remains one of the important taxane anticancer agents for patients with metastatic CRPC 6 . DTX binds to polymerized microtubules and inhibits cell mitosis, 7 and although initially effective, almost all patients with CRPC eventually become refractory.…”
Section: Introductionmentioning
confidence: 99%
“…However, once castration resistance is acquired, it will not respond to ADT, and recurrence and metastasis will occur as castration‐resistant prostate cancer (CRPC). Recently, various novel hormone treatment drugs and their combinations have appeared, 2–5 but docetaxel (DTX) remains one of the important taxane anticancer agents for patients with metastatic CRPC 6 . DTX binds to polymerized microtubules and inhibits cell mitosis, 7 and although initially effective, almost all patients with CRPC eventually become refractory.…”
Section: Introductionmentioning
confidence: 99%
“…However, acquired resistance to the drug eventually emerges. 3,4 Thereafter, it is definitely imperative to search for novel therapeutic agents with new mode of action.…”
Section: Introductionmentioning
confidence: 99%
“…10 6 PC-3 cells were injected subcutaneously into right flank of nude mice. When tumor volume reached 50-100 mm3 , tumorbearing mice were divided into 3 groups (5 mice per group) and started the treatment. Enoxacin (1 and 2 mg/kg) was given by intraperitoneal injection 3 times per week, mice treated with PBS as negative control.…”
mentioning
confidence: 99%
See 1 more Smart Citation